Ubenimex - Eiger Biopharmaceuticals/Nippon Kayaku

Drug Profile

Ubenimex - Eiger Biopharmaceuticals/Nippon Kayaku

Alternative Names: 1580RB; Bestatin; NK 421; Ubestatin

Latest Information Update: 03 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Microbial Chemistry
  • Developer Eiger BioPharmaceuticals, Inc.; Nippon Kayaku
  • Class Antineoplastics; Branched-chain amino acids; Dipeptides; Essential amino acids; Small molecules
  • Mechanism of Action Aminopeptidase B inhibitors; Aminopeptidase inhibitors; Immunostimulants; Leukotriene A4 hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute nonlymphocytic leukaemia
  • Phase II Lymphoedema
  • Preclinical Inflammation
  • Discontinued HIV infections; Pulmonary arterial hypertension

Most Recent Events

  • 01 Aug 2018 Eiger BioPharmaceuticals terminates the extension phase II LIBERTY2 trial for Pulmonary arterial hypertension in USA and Canada following the failure to demonstrate efficacy in EIG-UBX-001 trial (PO) (NCT02736149)
  • 24 Jun 2018 Biomarkers information updated
  • 16 Jan 2018 Discontinued - Phase-II for Pulmonary arterial hypertension in Canada, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top